Compare Stocks → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AUTLNASDAQ:CLLSNASDAQ:KRYSNASDAQ:PASGNASDAQ:VCEL Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUTLAutolus Therapeutics$4.09+0.2%$5.74$1.64▼$7.45$1.09B1.91.55 million shs1.82 million shsCLLSCellectis$2.45-1.6%$2.63$0.96▼$3.77$136.17M3.1242,576 shs216,957 shsKRYSKrystal Biotech$156.72+0.7%$163.46$82.09▼$189.97$4.47B0.85362,575 shs76,480 shsPASGPassage Bio$1.27+4.1%$1.38$0.58▼$1.79$78.25M1.3349,252 shs56,181 shsVCELVericel$45.96+1.1%$47.44$30.16▼$53.05$2.22B1.71535,059 shs47,806 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUTLAutolus Therapeutics-3.09%-15.00%-33.87%-31.31%+148.78%CLLSCellectis-0.40%+0.81%-0.40%-16.16%+30.37%KRYSKrystal Biotech-2.12%-5.06%-10.62%+34.17%+82.04%PASGPassage Bio-1.61%+1.67%-3.94%+25.77%+28.22%VCELVericel-1.43%+3.63%-8.29%+6.69%+48.72%Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (Ad)Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guideMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAUTLAutolus Therapeutics3.1815 of 5 stars3.44.00.00.02.53.30.6CLLSCellectis2.4734 of 5 stars3.52.00.00.01.52.51.3KRYSKrystal Biotech4.5546 of 5 stars3.51.00.04.72.73.31.9PASGPassage Bio2.5524 of 5 stars3.52.00.00.01.82.51.3VCELVericel0.4952 of 5 stars1.50.00.00.02.70.81.9Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAUTLAutolus Therapeutics2.80Moderate Buy$8.1699.51% UpsideCLLSCellectis3.00Buy$8.50246.94% UpsideKRYSKrystal Biotech3.00Buy$171.009.11% UpsidePASGPassage Bio3.00Buy$9.33634.91% UpsideVCELVericel3.00Buy$46.400.96% UpsideCurrent Analyst RatingsLatest AUTL, KRYS, VCEL, PASG, and CLLS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/22/2024KRYSKrystal BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$200.004/16/2024KRYSKrystal BiotechStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$178.00 ➝ $204.004/12/2024AUTLAutolus TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.004/9/2024AUTLAutolus TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$10.00 ➝ $11.003/26/2024VCELVericelTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$54.003/18/2024AUTLAutolus TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$9.00 ➝ $10.003/14/2024AUTLAutolus TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.003/5/2024PASGPassage BioCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.003/1/2024VCELVericelTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$51.00 ➝ $54.003/1/2024VCELVericelHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$46.00 ➝ $53.002/27/2024KRYSKrystal BiotechGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$130.00 ➝ $175.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAUTLAutolus Therapeutics$1.70M639.80N/AN/A$0.64 per share6.39CLLSCellectis$25.73M5.29N/AN/A$2.76 per share0.89KRYSKrystal Biotech$50.70M88.13N/AN/A$27.60 per share5.68PASGPassage BioN/AN/AN/AN/A$2.03 per shareN/AVCELVericel$197.52M11.26$0.02 per share2,616.62$4.73 per share9.72Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAUTLAutolus Therapeutics-$208.38M-$1.19N/AN/AN/AN/A-105.75%-49.25%5/14/2024 (Confirmed)CLLSCellectis-$106.14M-$1.67N/AN/AN/A-346.65%-73.03%-32.22%5/2/2024 (Estimated)KRYSKrystal Biotech$10.93M$0.081,959.2439.58N/AN/A-13.31%-12.61%5/13/2024 (Estimated)PASGPassage Bio-$102.06M-$1.86N/AN/AN/AN/A-73.12%-56.17%5/9/2024 (Estimated)VCELVericel-$3.18M-$0.09N/A91.92N/A-1.61%-1.55%-1.02%5/8/2024 (Confirmed)Latest AUTL, KRYS, VCEL, PASG, and CLLS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2024N/AAUTLAutolus Therapeutics-$0.10N/A+$0.10N/AN/AN/A 5/8/2024N/AVCELVericel-$0.11N/A+$0.11N/AN/AN/A 3/14/2024Q4 2023AUTLAutolus Therapeutics-$0.26-$0.44-$0.18-$0.44N/AN/A3/4/2024Q4 2023PASGPassage Bio-$0.41-$0.30+$0.11-$0.30N/AN/A2/29/2024Q4 2023VCELVericel$0.18$0.26+$0.08$0.26$64.28 million$65.00 million 2/26/202412/31/2023KRYSKrystal Biotech-$0.52$0.30+$0.82$0.30$27.43 million$42.14 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAUTLAutolus TherapeuticsN/AN/AN/AN/AN/ACLLSCellectisN/AN/AN/AN/AN/AKRYSKrystal BiotechN/AN/AN/AN/AN/APASGPassage BioN/AN/AN/AN/AN/AVCELVericelN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAUTLAutolus TherapeuticsN/A6.156.15CLLSCellectis0.572.202.20KRYSKrystal BiotechN/A17.7617.55PASGPassage BioN/A7.227.22VCELVericelN/A4.494.21OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAUTLAutolus Therapeutics72.83%CLLSCellectis63.90%KRYSKrystal Biotech86.29%PASGPassage Bio53.48%VCELVericelN/AInsider OwnershipCompanyInsider OwnershipAUTLAutolus Therapeutics25.70%CLLSCellectis16.41%KRYSKrystal Biotech14.10%PASGPassage Bio12.40%VCELVericel5.20%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAUTLAutolus Therapeutics463265.93 million197.58 millionOptionableCLLSCellectis23155.58 million46.46 millionOptionableKRYSKrystal Biotech22928.51 million24.49 millionOptionablePASGPassage Bio5861.61 million53.97 millionOptionableVCELVericel31448.38 million45.86 millionOptionableAUTL, KRYS, VCEL, PASG, and CLLS HeadlinesSourceHeadlineHere's Why Shareholders May Want To Be Cautious With Increasing Vericel Corporation's (NASDAQ:VCEL) CEO Pay Packetfinance.yahoo.com - April 26 at 8:48 AMNew York State Common Retirement Fund Sells 30,717 Shares of Vericel Co. (NASDAQ:VCEL)marketbeat.com - April 25 at 8:29 AMVericel to Report First-Quarter 2024 Financial Results on May 8, 2024globenewswire.com - April 24 at 8:30 AMFederated Hermes Inc. Has $19.96 Million Stock Position in Vericel Co. (NASDAQ:VCEL)marketbeat.com - April 22 at 5:56 AMVericel Corporation (VCEL) stock historical prices & data – Yahoo Financenz.finance.yahoo.com - April 21 at 11:52 PMDominick Colangelo Sells 17,500 Shares of Vericel Co. (NASDAQ:VCEL) Stockinsidertrades.com - April 21 at 4:32 AMVericel Co. (NASDAQ:VCEL) CEO Sells $780,325.00 in Stockinsidertrades.com - April 20 at 7:12 AMVericel Co. (NASDAQ:VCEL) CEO Dominick Colangelo Sells 17,500 Sharesmarketbeat.com - April 19 at 6:44 PMKnights of Columbus Asset Advisors LLC Purchases 112,169 Shares of Vericel Co. (NASDAQ:VCEL)marketbeat.com - April 19 at 1:38 PMVericel Corpmoney.usnews.com - April 17 at 9:10 PMMutual of America Capital Management LLC Sells 21,706 Shares of Vericel Co. (NASDAQ:VCEL)marketbeat.com - April 15 at 5:51 AMVericel Corporation (NASDAQ:VCEL) On The Verge Of Breaking Evenfinance.yahoo.com - April 13 at 1:24 PMVericel Co. (NASDAQ:VCEL) Sees Large Increase in Short Interestmarketbeat.com - April 12 at 10:31 AMVericel Co. (NASDAQ:VCEL) Shares Acquired by Conestoga Capital Advisors LLCmarketbeat.com - April 10 at 3:55 PMVericel Co. (NASDAQ:VCEL) Given Average Rating of "Buy" by Brokeragesmarketbeat.com - April 8 at 4:13 AMCommit To Buy Vericel At $25, Earn 9% Annualized Using Optionsnasdaq.com - April 7 at 10:47 PMVericel Co. (NASDAQ:VCEL) Director Robert L. Md Zerbe Sells 3,278 Sharesinsidertrades.com - March 30 at 7:35 AMVericel Co. (NASDAQ:VCEL) Stock Holdings Decreased by SG Americas Securities LLCmarketbeat.com - March 30 at 4:17 AMVericel (NASDAQ:VCEL) Sets New 1-Year High at $51.40marketbeat.com - March 27 at 11:23 AMAnalyst Scoreboard: 5 Ratings For Vericelmarkets.businessinsider.com - March 27 at 1:54 AMTruist Financial Reaffirms "Buy" Rating for Vericel (NASDAQ:VCEL)marketbeat.com - March 26 at 9:35 AMVericel Co. (NASDAQ:VCEL) COO Sells $352,046.54 in Stockinsidertrades.com - March 14 at 9:39 AMVericel Co. (NASDAQ:VCEL) SVP Sells $367,852.95 in Stockinsidertrades.com - March 12 at 4:46 AMVCEL Oct 2024 50.000 callca.finance.yahoo.com - March 3 at 7:05 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAutolus TherapeuticsNASDAQ:AUTLAutolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It also focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.CellectisNASDAQ:CLLSCellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.Krystal BiotechNASDAQ:KRYSKrystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.Passage BioNASDAQ:PASGPassage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.VericelNASDAQ:VCELVericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.